Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge.

IF 3.6 Q1 TROPICAL MEDICINE
Qudus Olajide Lawal, Joseph Okoeguale, Sebastine Oseghae Oiwoh, ThankGod Akhigbe, Reuben Agbons Eifediyi, Sylvanus Akhalufo Okogbenin
{"title":"Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge.","authors":"Qudus Olajide Lawal, Joseph Okoeguale, Sebastine Oseghae Oiwoh, ThankGod Akhigbe, Reuben Agbons Eifediyi, Sylvanus Akhalufo Okogbenin","doi":"10.1186/s41182-024-00609-0","DOIUrl":null,"url":null,"abstract":"<p><p>Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease.</p>","PeriodicalId":23311,"journal":{"name":"Tropical Medicine and Health","volume":"52 1","pages":"46"},"PeriodicalIF":3.6000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229249/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Medicine and Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41182-024-00609-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"TROPICAL MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease.

解决拉沙热治疗瓶颈:克服利巴韦林肠外制剂的挑战。
利巴韦林安瓿制剂仍然是治疗拉沙热疾病的一大挑战。拉沙热是西非次区域的一种地方性病毒性出血热,其治疗标准是大剂量利巴韦林。由于需要大剂量治疗,因此 200 毫克/毫升安瓿剂量的利巴韦林是一项艰巨的任务,尤其是在疾病爆发期间。本评论强调了这一挑战,并热情呼吁调整安瓿剂量,以适应拉沙热疾病的大剂量要求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tropical Medicine and Health
Tropical Medicine and Health TROPICAL MEDICINE-
CiteScore
7.00
自引率
2.20%
发文量
90
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信